Immunocore Holdings plc American Depositary Shares (IMCR)
Company News
Immunocore Plc reported Q2 2025 results with 30% revenue growth to $98.0 million, driven by KIMMTRAK sales. Despite revenue success, the company experienced a net loss and continued investing heavily in research and development across multiple clinical programs.
Immunocore's HIV functional cure candidate IMC-M113V showed promising safety and signals of dose-dependent viral control in a Phase 1/2 trial, with some patients maintaining viral suppression for up to 12 weeks after stopping antiretroviral treatment.
14 analysts have shared their evaluations of Immunocore Hldgs (NASDAQ:IMCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 3 1 1 0 0 2M Ago 2 0 0 0 0 3M Ago 3 2 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $81.79, along with a high estimate of $100.00 and a low estimate of $63.00. This current average has increased by 7.21% from the previous average price target of $76.29. Diving into Analyst Ratings: An In-Depth Exploration The standing of Immunocore Hldgs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Gil Blum Needham Maintains Buy $81.00 - Graig Suvannavejh Mizuho Lowers Buy $88.00 $90.00 Bill Maughan Canaccord Genuity Raises Hold $67.00 $63.00 Patrick Trucchio HC Wainwright & Co. Raises Buy $100.00 $90.00 Gil Blum Needham Maintains Buy $81.00 - Jonathan Chang Leerink Partners Announces Outperform $74.00 - Michael Schmidt Guggenheim Maintains Buy $92.00 - Gil Blum Needham Maintains Buy $81.00 - Jessica Fye JP Morgan Raises Overweight $70.00 $60.00 Patrick Trucchio HC Wainwright & Co. Maintains Buy $90.00 - Graig Suvannavejh Mizuho Raises Buy $90.00 $86.00 Justin Kim Oppenheimer Raises Outperform $87.00 $85.00 Bill Maughan Canaccord Genuity Raises Hold $63.00 $60.00 Gil Blum Needham Maintains Buy $81.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related ...Full story available on Benzinga.com
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.